6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis by Romy M. W. Kremers (819412)

<i>Ann5G26EG28E</i> or <i>Ann5G257EG259E</i> overexpression decreased the resistance of pollen to BFA compared with <i>Ann5</i> overexpression. by Jingen Zhu (597699)

Reduced RabGEF1 expression decreases NGF-induced TrkA phosphorylation but not TrkA internalization. by See-Ying Tam (828866)

Graphs of marginal mean values of the studied parameters for dolphin kick, flutter kick and breaststroke kick with and without diving gear (Parameters that were not statistically d... by Marek Rejman (9199616)

Kaplan-Meier survival curves for overall survival of MBC by highest tertile of IFN-γ signature vs. the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Study flow diagram. by Christina Gillezeau (5348660)

Subjects:

Kaplan–Meier survival curves for overall survival of NMIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Sample flow diagram. by Christina Gillezeau (5348660)

Subjects:

Kaplan-Meier survival curves for overall survival of MIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Kaplan-Meier survival curves for progression-free survival of MIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Characteristics of bladder cancer patients by stage. by Christina Gillezeau (5348660)

Subjects:

Hazard ratios (HR) and 95% confidence intervals (CI) for the association between INF- γ signature levels and death among bladder cancer patients by stage. by Christina Gillezeau (5348660)

Subjects:

Compared the maximum adsorption capacity of CR onto magnetic Co_0.5Mn_0.5Fe₂O₄ nanoparticles with other adsorbents. by Xiajun Zhang (3161865)

Subjects:

ODE model fit is average of many DS simulations. by Apeksha Singh (8174256)

Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates. by Xiaoyan Xia (560153)

“…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”